Menu

Novartis to Refund Covered Entities After Adjusting 340B Ceiling Prices for 100-Plus Products

Shannon Young, Associate Editor/Senior Writer 340B Report Views
Drugmaker Novartis filed suit to block Maryland's recently signed 340B contract pharmacy statute.
Thousands of covered entities that purchased more than one hundred Novartis products between late 2019 and early 2023 will be [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Post Navigation

COLUMN: Despite 340B Opponents’ Unprecedented Tactics, Many States Progress on Contract Pharmacy Protection Legislation

Maine Issues Draft Rule for 340B Hospital Reporting Requirements with New Data, Enforcement Provisions

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live

Sliding Sidebar

Link to spotlight on Sean Hall of Visante

340B Report Categories

More Categories

Recent Articles

Article Archives